ALX Oncology (ALXO) Revenue & Revenue Breakdown
ALX Oncology Revenue Highlights
ALX Oncology Revenue by Period
ALX Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $1.18M | -75.35% |
| 2019-12-31 | $4.80M | 132.03% |
| 2018-12-31 | $2.07M | - |
ALX Oncology generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
ALX Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.48M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $1.18 | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $527.00K | -19.54% |
| 2020-03-31 | $655.00K | -46.00% |
| 2019-12-31 | $1.21M | -3.42% |
| 2019-09-30 | $1.26M | -3.01% |
| 2019-06-30 | $1.29M | 25.48% |
| 2019-03-31 | $1.03M | - |
ALX Oncology generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
ALX Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IMTX | Immatics | $54.00M | $30.45M |
| EYPT | EyePoint Pharmaceuticals | $46.02M | $9.48M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| BCEL | Atreca | $770.00K | $80.00K |
| CGEM | Cullinan Oncology | - | - |
| ALXO | ALX Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| CABA | Cabaletta Bio | - | - |
| BCAB | BioAtla | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| DYN | Dyne Therapeutics | - | - |
| VIRX | Viracta Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
ALXO Revenue FAQ
What is ALX Oncology’s yearly revenue?
ALX Oncology's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ALXO's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is ALX Oncology’s quarterly revenue?
ALX Oncology's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ALXO's quarterly revenue for Q4 2023 was $2.48M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is ALX Oncology’s revenue growth rate?
ALX Oncology's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.